• Gene fusion; HGNC; HGNC:13575; BRD4 + HGNC; HGNC:29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT; Note=BRD4 exon 14 fused to NUTM1 exon 2 (PubMed=24736545; PubMed=28203693; PubMed=29348827).
  

PubMed=1730520; DOI=10.1002/ijc.2910500216
Kuzume T., Kubonishi I., Takeuchi S., Takeuchi T., Iwata J., Sonobe H., Ohtsuki Y., Miyoshi I.
Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality.
Int. J. Cancer 50:259-264(1992)

PubMed=21447744; DOI=10.1158/0008-5472.CAN-10-3513; PMCID=PMC3070805
Schwartz B.E., Hofer M.D., Lemieux M.E., Bauer D.E., Cameron M.J., West N.H., Agoston E.S., Reynoird N., Khochbin S., Ince T.A., Christie A.L., Janeway K.A., Vargas S.O., Perez-Atayde A.R., Aster J.C., Sallan S.E., Kung A.L., Bradner J.E., French C.A.
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Cancer Res. 71:2686-2696(2011)

PubMed=24736545; DOI=10.1158/0008-5472.CAN-13-2658; PMCID=PMC4097982
Wang R.-R., Liu W., Helfer C.M., Bradner J.E., Hornick J.L., Janicki S.M., French C.A., You J.-X.
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Cancer Res. 74:3332-3343(2014)

PubMed=28203693; DOI=10.1093/annonc/mdw686; PMCID=PMC5378225
Lee J.-K., Louzada S., An Y., Kim S.Y., Kim S., Youk J., Park S., Koo S.H., Keam B., Jeon Y.K., Ku J.-L., Yang F.-T., Kim T.M., Ju Y.S.
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Ann. Oncol. 28:890-897(2017)

PubMed=29348827; DOI=10.18632/oncotarget.22862; PMCID=PMC5762512
Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.
Oncotarget 8:112313-112329(2017)